title: Personalized chemotherapy profiling using cancer cell lines from selectable mice.
abstract: OBJECTIVE
  High-throughput chemosensitivity testing of low-passage cancer cell lines can be used to prioritize agents for personalized chemotherapy. However, generating cell lines from primary cancers is difficult because contaminating stromal cells overgrow the malignant cells.
  
  
  METHODS
  We produced a series of hypoxanthine phosphoribosyl transferase (hprt)-null immunodeficient mice. During growth of human cancers in these mice, hprt-null murine stromal cells replace their human counterparts.
  
  
  RESULTS
  Pancreatic and ovarian cancers explanted from these mice were grown in selection media to produce pure human cancer cell lines. We screened one cell line with a 3,131-drug panel and identified 77 U.S. Food and Drug Administration (FDA)-approved drugs with activity, and two novel drugs to which the cell line was uniquely sensitive. Xenografts of this carcinoma were selectively responsive to both drugs.
  
  
  CONCLUSIONS
  Chemotherapy can be personalized using patient-specific cell lines derived in biochemically selectable mice.
authors: The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
authors: Hirohiko
authors: H
authors: Kamiyama
authors: Sherri
authors: S
authors: Rauenzahn
authors: Joong Sup
authors: JS
authors: Shim
authors: Collins A
authors: CA
authors: Karikari
authors: Georg
authors: G
authors: Feldmann
authors: Li
authors: L
authors: Hua
authors: Mihoko
authors: M
authors: Kamiyama
authors: F William
authors: FW
authors: Schuler
authors: Ming-Tseh
authors: MT
authors: Lin
authors: Robert M
authors: RM
authors: Beaty
authors: Balasubramanyam
authors: B
authors: Karanam
authors: Hong
authors: H
authors: Liang
authors: Michael E
authors: ME
authors: Mullendore
authors: Guanglan
authors: G
authors: Mo
authors: Manuel
authors: M
authors: Hidalgo
authors: Elizabeth
authors: E
authors: Jaffee
authors: Ralph H
authors: RH
authors: Hruban
authors: H A
authors: HA
authors: Jinnah
authors: Richard B S
authors: RB
authors: Roden
authors: Antonio
authors: A
authors: Jimeno
authors: Jun O
authors: JO
authors: Liu
authors: Anirban
authors: A
authors: Maitra
authors: James R
authors: JR
authors: Eshleman
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002316:Cardiotonic Agents / Q000494:pharmacology; D004074:Digitoxin / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D053631:Interleukin Receptor Common gamma Subunit; D008297:Male; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D009621:Nogalamycin / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D057285:Precision Medicine; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D014407:Tumor Cells, Cultured
chemical_list: D000903:Antibiotics, Antineoplastic; D002316:Cardiotonic Agents; D053631:Interleukin Receptor Common gamma Subunit; D004074:Digitoxin; D007041:Hypoxanthine Phosphoribosyltransferase; D009621:Nogalamycin